Tactile Systems Technology (Tactile Systems Technology) ROCE % : 20.25% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Tactile Systems Technology ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Tactile Systems Technology's annualized ROCE % for the quarter that ended in Dec. 2023 was 20.25%.

Tactile Systems Technology ROCE % Historical Data

The historical data trend for Tactile Systems Technology's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tactile Systems Technology ROCE % Chart

Tactile Systems Technology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

9.49

-2.61

-0.99

-6.37

8.37

Tactile Systems Technology Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															16.37	-7.34	3.66	8.32	20.25

Tactile Systems Technology ROCE % Calculation

Tactile Systems Technology's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	18.041	/	( ( (254.996 - 64.33)	+	(281.438 - 41.057) )	/ 2 )
	=	18.041	/	( (190.666	+	240.381)	/ 2 )
	=	18.041	/	215.5235
	=	8.37 %

Tactile Systems Technology's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	49.428	/	( ( (293.307 - 45.618)	+	(281.438 - 41.057) )	/ 2 )
	=	49.428	/	( ( 247.689	+	240.381 )	/ 2 )
	=	49.428	/	244.035
	=	20.25 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Tactile Systems Technology (NAS:TCMD) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Tactile Systems Technology ROCE % Related Terms

Thank you for viewing the detailed overview of Tactile Systems Technology's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Tactile Systems Technology (Tactile Systems Technology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Tactile Systems Technology Inc (NAS:TCMD) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

3L3:Germany

Address

3701 Wayzata Boulevard, Suite 300, Minneapolis, MN, USA, 55416

Website

https://www.tactilemedical.com

Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.

Executives

Boyd Vindell Washington	director	1331 TYLER STREET NE, STE 200, MINNEAPOLIS MN 55413
Daniel L. Reuvers	director, officer: President and CEO	INTEGRA LIFESCIENCES CORPORATION, 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Sherri Lee Ferstler	officer: Senior VP, Sales	1331 TYLER STREET NE, STE 200, MINNEAPOLIS MN 55413
William W Burke	director	3868 MOCKINGBIRD LN, DALLAS TX 75205
Kristie Burns	officer: Sr. VP Mktg & Clinical Affairs	3701 WAYZATA BLVD, MINNEAPOLIS MN 55416
Eric Pauls	officer: Senior VP, Sales	3701 WAYZATA BLVD, SUITE 300, MINNEAPOLIS MN 55416
Elaine M. Birkemeyer	officer: Chief Financial Officer	3701 WAYZATA BLVD, SUITE 300, MINNEAPOLIS MN 55416
Brent Moen	officer: Chief Financial Officer	3600 HOLLY LANE NORTH, SUITE 40, PLYMOUTH MN 55447
Carmen B Volkart	director	C/O MODULAR MEDICAL, INC., 16772 WEST BERNARDO DRIVE, SAN DIEGO CA 92127
Valerie L. Asbury	director	3701 WAYZATA BLVD, SUITE 300, MINNEAPOLIS MN 55416
David Brent Shafer	director	2800 ROCKCREEK PARKWAY, NORTH KANSAS CITY MO 64117
Bryan Rishe	officer: Vice President, Sales	1331 TYLER STREET NE, SUITE 200, MINNEAPOLIS MN 55413
Deepti Jain	director	3701 WAYZATA BLVD, MINNEAPOLIS MN 55416
Sheri Louise Dodd	director	3701 WAYZATA BLVD, SUITE 300, MINNEAPOLIS MN 55416
Gerald R. Mattys	director, officer: Chief Executive Officer	1331 TYLER STREET NE, SUITE 200, MINNEAPOLIS MN 55413